Quantcast

Latest Oligonucleotide Stories

2010-09-09 09:17:00

BASKING RIDGE, N.J., Sept. 9 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel located at 200 Boylston Street in Boston, Massachusetts. Dr. Mazzo's presentation will be given at 2:40 pm EDT in the Winthrop Room and will include an overview of the Company's...

2010-07-27 09:17:00

BASKING RIDGE, N.J., July 27 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, Ph.D., President and CEO, will be presenting at Wedbush Securities Life Sciences Best Ideas MAC: Management Access Conference at the Parker Meridien Hotel in New York City on August 3, 2010. Dr. Mazzo's presentation will be given at 8:00 a.m. EDT in the Lorica Room and will include an...

2010-07-12 13:26:46

Antisense oligonucleotides delivered into spinal cords of adult and neonatal mice provide a long term rescue from disease symptoms The devastating, currently incurable motor-neuron disease spinal muscular atrophy (SMA) might soon be treated with tiny, chemically modified pieces of RNA called antisense oligonucleotides (ASOs). Scientists at Cold Spring Harbor Laboratory (CSHL) and California-based Isis Pharmaceuticals have succeeded in reversing symptoms of Type III SMA, a relatively mild form...

2010-06-17 08:30:00

BASKING RIDGE, N.J., June 17 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the 2010 Wells Fargo Healthcare Conference at the InterContinental Hotel in Boston, Massachusetts. Dr. Mazzo's presentation will be given at 8:00 am (EDT) on Thursday, June 24 in the Robinson Room and will include an overview of the Company's...

2010-06-17 06:00:00

- Japanese patent issuances facilitate commercialization of MCC in Japan - BELLEVILLE, ON, June 17 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition and its Oligonucleotide technology platform. The following is a list of the Bioniche MCC patent applications that have been allowed or...

2010-06-08 08:30:00

BASKING RIDGE, N.J., June 8 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Jefferies 2010 Global Life Sciences Conference in New York City held June 8-11, 2010. At this invitation-only event, Dr. Mazzo's presentation will be given at 1:15 pm (EDT) on Friday, June 11 in Track E and will include an overview of the...

2010-06-07 08:30:00

BASKING RIDGE, N.J., June 7 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the 9th Annual Needham Healthcare Conference at the New York Palace Hotel in New York City. Dr. Mazzo's presentation will be given at 10:40am (EDT) on Thursday, June 10 in the Chairman's Office and will include an overview of the Company's pipeline...

2010-05-25 08:30:00

BASKING RIDGE, N.J., May 25 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, today announced issuance of another key patent related to their proprietary technology. This new patent includes coverage for RB007, the modulator or active control component of Regado's innovative product candidates, the REG1 and REG2 anticoagulation systems. The allowed claims in U.S. Patent No. 7,723,315 broadly...

2010-05-12 07:00:00

SAN DIEGO, May 12 /PRNewswire/ -- TriLink BioTechnologies, Inc. (TriLink), a key manufacturer of high quality oligonucleotides and nucleoside triphosphates, announced the launch of its new website and OligoBuilder® online oligonucleotide ordering system. TriLink's in-house marketing and design team utilized extensive user feedback and survey results to design a customer-centric website. The site renovation embodies TriLink's commitment to their customers. The website,...

2010-04-30 08:30:00

BASKING RIDGE, N.J., April 30 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at the BIO International Convention at McCormick Place in Chicago, Illinois. Ms. McDonald's presentation, scheduled on May 5, 2010 will begin at 3:30pm, CDT and will include an overview of the Company's pipeline...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related